225 related articles for article (PubMed ID: 27899770)
1. [Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective].
Fukuda A; Igarashi A
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1311-1315. PubMed ID: 27899770
[TBL] [Abstract][Full Text] [Related]
2. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
3. Japanese universal health care faces a crisis in cancer treatment.
Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
[No Abstract] [Full Text] [Related]
4. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
Shiroiwa T; Fukuda T; Ikeda S; Takura T
Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
[TBL] [Abstract][Full Text] [Related]
5. Joint Symposium of Korean Cancer Association & UICC-ARO-Cross-boundary cancer studies: cancer and Universal Health Coverage (UHC) in Asia.
Park EC; Kawahara N; Nozaki S; Thabrany H; Yoshimi S; Park S; Lee DH; Akaza H; Roh JK
Jpn J Clin Oncol; 2017 Sep; 47(9):889-895. PubMed ID: 28903533
[TBL] [Abstract][Full Text] [Related]
6. Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage.
Paolucci F; Redekop K; Fouda A; Fiorentini G
Appl Health Econ Health Policy; 2017 Dec; 15(6):697-706. PubMed ID: 28871512
[TBL] [Abstract][Full Text] [Related]
7. Comparison of New Drug Accessibility and Price Between Japan and Major European Countries.
Takayama A; Narukawa M
Ther Innov Regul Sci; 2017 Sep; 51(5):604-611. PubMed ID: 30231682
[TBL] [Abstract][Full Text] [Related]
8. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
9. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
10. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment in Japan: a work in progress.
Kamae I; Thwaites R; Hamada A; Fernandez JL
J Med Econ; 2020 Apr; 23(4):317-322. PubMed ID: 31944134
[No Abstract] [Full Text] [Related]
12. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Thatte U; Hussain S; de Rosas-Valera M; Malik MA
Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
[TBL] [Abstract][Full Text] [Related]
14. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
[TBL] [Abstract][Full Text] [Related]
15. Japanese Cancer Association Meeting UICC International session--what is cost-effectiveness in cancer treatment?
Akaza H; Kawahara N; Roh JK; Inoue H; Park EC; Lee KS; Kim S; Hayre J; Naidoo B; Wilkinson T; Fukuda T; Jang WI; Nogimori M
Asian Pac J Cancer Prev; 2014; 15(1):3-10. PubMed ID: 24528045
[TBL] [Abstract][Full Text] [Related]
16. PAHO'S Strategy for Universal Access to Health and Universal Health Coverage: implications for health services and hospitals in LAC.
Holder R; Fabrega R
World Hosp Health Serv; 2015; 51(2):4-6. PubMed ID: 26521377
[TBL] [Abstract][Full Text] [Related]
17. How much is the life of a cancer patient worth? A pharmaco-economic perspective.
Simoens S; Dooms M
J Clin Pharm Ther; 2011 Jun; 36(3):249-56. PubMed ID: 21545607
[TBL] [Abstract][Full Text] [Related]
18. How changes to Irish healthcare financing are affecting universal health coverage.
Briggs AD
Health Policy; 2013 Nov; 113(1-2):45-9. PubMed ID: 23992755
[TBL] [Abstract][Full Text] [Related]
19. [Drug Vial Optimization(DVO)for Anti-Cancer Drugs].
Iwamoto T
Gan To Kagaku Ryoho; 2017 May; 44(5):353-356. PubMed ID: 28536326
[TBL] [Abstract][Full Text] [Related]
20. Costs and benefits of improving access to psychotherapies for common mental disorders.
Dezetter A; Briffault X; Ben Lakhdar C; Kovess-Masfety V
J Ment Health Policy Econ; 2013 Dec; 16(4):161-77. PubMed ID: 24526585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
